Compare GraniteShares 2x Long NVDA Daily ETF (NVDL) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GraniteShares 2x Long NVDA Daily ETF vs BIO-TECHNE Corp — how do they compare? GraniteShares 2x Long NVDA Daily ETF trades at $37.11 (market cap $3.56B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: BIO-TECHNE Corp is far larger — about 3.2× GraniteShares 2x Long NVDA Daily ETF's market cap, and BIO-TECHNE Corp pays a 0.44% dividend while GraniteShares 2x Long NVDA Daily ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold GraniteShares 2x Long NVDA Daily ETF for 15 Days and BIO-TECHNE Corp for 63 Days on average.
| NVDL | TECH | |
|---|---|---|
Market Cap | $3.56B | $11.36B |
Volume | 9,740,643 | 5,390,331 |
Sector | Leveraged / Inverse | Health |
52-Week High | $43.02 | $72.61 |
52-Week Low | $21.76 | $43.31 |
Typical Hold Time | 15 Days | 63 Days |
Enterprise Value | — | $11.39B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NVDL, the GraniteShares 2x Long NVDA Daily ETF, trades at $37.335, down 5.65% on the day. Technical indicators show a bullish overall signal with strong moving average support, though oscillators remain neutral. Recent news highlights Nvidia's continued AI leadership and earnings beats, driving leveraged ETF interest. The ETF aims to deliver 2x daily returns of Nvidia stock, with technical analysis showing support at $36 and resistance at $38-39 levels.
The outlook remains tied to Nvidia's AI dominance and earnings performance. Investment opportunity exists through leveraged exposure to Nvidia's growth trajectory, though risks include daily reset leverage decay and Nvidia's high valuation. Recent SpaceX earnings have reshuffled AI chip trades, creating volatility. The ETF's performance depends on Nvidia maintaining its AI market leadership and execution.
Bio-Techne (TECH) trades at $72.47, down 0.08% on the day, near its 52-week high of $72.70 (Defense World, 2026-09-28). The stock shows a bullish technical trend with strong moving average signals. Recent shareholder approval of the acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23) is a key catalyst. Q2 2026 earnings beat expectations with EPS of $0.52 versus $0.519 expected, though net income margin has declined from 25.09% in 2023 to 14.96% in 2026.
The pending acquisition offers a near-term upside to the current price, but high valuation ratios (P/E of 62.46, P/S of 9.36) pose a risk if the deal faces regulatory hurdles. Analyst consensus is mixed with 46% Buy and 54% Hold ratings. The stock presents a favorable risk-reward for investors seeking a takeover arbitrage opportunity, with the primary risk being deal failure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
